featured
Pacritinib vs Best Available Therapy in Myelofibrosis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial
JAMA Oncol 2018 Mar 08;[EPub Ahead of Print], J Mascarenhas, R Hoffman, M Talpaz, AT Gerds, B Stein, V Gupta, A Szoke, M Drummond, A Pristupa, T Granston, R Daly, S Al-Fayoumi, JA Callahan, JW Singer, J Gotlib, C Jamieson, C Harrison, R Mesa, S VerstovsekFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.